These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 22371311)

  • 1. H3 or H4 histamine receptors: that which contributes to suppressing human cholangiocarcinoma progression still remains to be clarified.
    He GH; Xu GL; Cai WK; Xia W
    Hepatology; 2012 Sep; 56(3):1182-3; author reply 1183. PubMed ID: 22371311
    [No Abstract]   [Full Text] [Related]  

  • 2. The H4 histamine receptor agonist, clobenpropit, suppresses human cholangiocarcinoma progression by disruption of epithelial mesenchymal transition and tumor metastasis.
    Meng F; Han Y; Staloch D; Francis T; Stokes A; Francis H
    Hepatology; 2011 Nov; 54(5):1718-28. PubMed ID: 21793031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The BH3-mimetic ABT-737 targets the apoptotic machinery in cholangiocarcinoma cell lines resulting in synergistic interactions with zoledronic acid.
    Romani AA; Desenzani S; Morganti MM; Baroni MC; Borghetti AF; Soliani P
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):557-67. PubMed ID: 20473610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adrenal metastasis from intrahepatic cholangiocarcinoma.
    Pandey D; Lee KH; Wong SY; Tan KC
    Liver Int; 2007 Sep; 27(7):1016. PubMed ID: 17696942
    [No Abstract]   [Full Text] [Related]  

  • 5. Regarding: epithelial-mesenchymal transition induced by hepatitis C virus core protein in cholangiocarcinoma.
    Balsano C; Conti B; Arciello M
    Ann Surg Oncol; 2011 Mar; 18(3):896; author reply 897. PubMed ID: 20645009
    [No Abstract]   [Full Text] [Related]  

  • 6. [The progress of chemotherapy for intrahepatic cholangiocarcinoma].
    Ioka T; Katayama K
    Nihon Shokakibyo Gakkai Zasshi; 2012 Nov; 109(11):1895-901. PubMed ID: 23132033
    [No Abstract]   [Full Text] [Related]  

  • 7. Fibroblast growth factor receptor 4 promotes progression and correlates to poor prognosis in cholangiocarcinoma.
    Xu YF; Yang XQ; Lu XF; Guo S; Liu Y; Iqbal M; Ning SL; Yang H; Suo N; Chen YX
    Biochem Biophys Res Commun; 2014 Mar; 446(1):54-60. PubMed ID: 24565842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic therapy for hepatocellular carcinoma and cholangiocarcinoma.
    Chung V
    Surg Oncol Clin N Am; 2015 Jan; 24(1):187-98. PubMed ID: 25444475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Futibatinib: paving the way to personalized medicine in intrahepatic cholangiocarcinoma.
    Khoury R; Chahine C; Ibrahim R; Khalife N; Saleh M; Saleh K
    Future Oncol; 2023 Jun; 19(17):1161-1163. PubMed ID: 37293779
    [No Abstract]   [Full Text] [Related]  

  • 10. [Systemic chemotherapy for cholangiocarcinoma].
    Furuse J; Suzuki E; Hirokawa S; Kitamura H; Nagashima F
    Nihon Shokakibyo Gakkai Zasshi; 2010 Jul; 107(7):1102-8. PubMed ID: 20616478
    [No Abstract]   [Full Text] [Related]  

  • 11. Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma.
    Lamarca A; Vogel A
    ESMO Open; 2023 Dec; 8(6):102049. PubMed ID: 37922686
    [No Abstract]   [Full Text] [Related]  

  • 12. Futibatinib (Lytgobi) for cholangiocarcinoma.
    Roskoski R
    Trends Pharmacol Sci; 2023 Mar; 44(3):190-191. PubMed ID: 36702680
    [No Abstract]   [Full Text] [Related]  

  • 13. [Photodynamic therapy for unresectable cholangiocarcinoma: does it really increase the survival time?].
    Choi EK; Kim MH
    Korean J Gastroenterol; 2005 Jun; 45(6):446; author reply 447. PubMed ID: 15973081
    [No Abstract]   [Full Text] [Related]  

  • 14. Painful Eruptions in a Patient With Cholangiocarcinoma Treated With Fibroblast Growth Factor Receptor Inhibitor.
    Wylie NS; Sokumbi O; Starr JS
    JAMA Oncol; 2021 Dec; 7(12):1891-1892. PubMed ID: 34709371
    [No Abstract]   [Full Text] [Related]  

  • 15. Partial treatment response to capmatinib in
    Lefler DS; Tierno MB; Bashir B
    Cancer Biol Ther; 2022 Dec; 23(1):112-116. PubMed ID: 35129063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Photodynamic therapy of nenresectable cholangiocarcinoma.
    Terruzzi V; Minoli G
    Gastrointest Endosc; 1999 Nov; 50(5):727-8. PubMed ID: 10576983
    [No Abstract]   [Full Text] [Related]  

  • 17. Chemotherapy impregnated plastic biliary endoprostheses: one small step for man(agement) of cholangiocarcinoma.
    Baron TH
    Hepatology; 2000 Nov; 32(5):1170-1. PubMed ID: 11050071
    [No Abstract]   [Full Text] [Related]  

  • 18. Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma.
    Jensen LH; Jakobsen A
    Expert Rev Anticancer Ther; 2011 Apr; 11(4):589-600. PubMed ID: 21504326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biliary photodynamic therapy alternative delivery technique.
    Burdick JS; Magee D; Miller G; Wright KB
    Endoscopy; 2000 Oct; 32(10):S63. PubMed ID: 11068847
    [No Abstract]   [Full Text] [Related]  

  • 20. What are the key challenges in the pharmacological management of cholangiocarcinoma?
    Ledenko M; Patel T
    Expert Opin Pharmacother; 2022 Apr; 23(5):531-533. PubMed ID: 34866539
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.